Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab
Authors:
Open Access
- 1 January 2003
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 42 (1) , 193-194
Abstract
Sir, As a result of the introduction of new disease-modifying anti-rheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA), patients with refractory RA tend to be treated with an increasing number of different DMARDs, alone or in combination. This improves the chances of achieving good disease control but also risks triggering adverse reactions.Keywords
This publication has 5 references indexed in Scilit:
- Adverse reactions to TNF-α inhibitors in rheumatoid arthritisThe Lancet, 2002
- Severe Pancytopenia after Leflunomide in Rheumatoid ArthritisActa Medica Austriaca, 2000
- Validation of rheumatoid arthritis improvement criteria that include simplified joint countsArthritis & Rheumatism, 1998
- Clinical characteristics related to methotrexate-induced pancytopeniaClinical Rheumatology, 1997
- Azathioprine and Allopurinol: The Price of an Avoidable Drug InteractionAnnals of Pharmacotherapy, 1996